ROR1 and neoplasm: Some patients treated with vaccines of autologous leukemia cells genetically engineered to promote anti-leukemia immune responses generated auto-antibodies specific for Ror1 that did not react with non-tumor tissues showing that this receptor is specific to cancer cells6.